Design Therapeutics, Inc.

DSGN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001807120

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $226.2M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 9, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$9.02 2026-11-20; market equity $577.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, "Design," "our company," "we," "us," and "our" refer to Design Therapeutics, Inc., a Delaware corporation. We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 56.6						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(6.5%)	(6.7%)		56.6	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 4.9						
Altman Z double-prime	15.76	0.31		4.3	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	17.14x	2.68x		5.5	781	2025-12-31
Growth and financing, sleeve percentile 61.2						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	(12.8%)	3.2%		73.1	663	2025-12-31
Net share issuance, one year	8.6%	1.6%		49.3	626	2026-03-02

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.1 months
Thin data	5 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	87.6%	(1.7%)	89
Distance from 52-week high	(43.4%)	(33.0%)	41
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(9.4%)	0.6%	30
Book value to price	0.35	0.29	56
Sales to price	0.00	0.38	0
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	0.46	(0.19)	89
Twelve-month failure probability, CHS model	0.04%	0.06%	42

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$15.3M
Operating cash flow, four quarters	-$59.3M
Months of runway	3.1
Days since last periodic filing	18 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$5.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$69.8M	2025-12-31	2026-03-09	10-K	26-098491
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$54.4M	2025-12-31	2026-03-09	10-K	26-098491
3	assets	us-gaap:Assets	$226.2M	2025-12-31	2026-03-09	10-K	26-098491
4	assets	us-gaap:Assets	$252.1M	2024-12-31	2026-03-09	10-K	26-098491
5	current assets	us-gaap:AssetsCurrent	$223.8M	2025-12-31	2026-03-09	10-K	26-098491
6	current liabilities	us-gaap:LiabilitiesCurrent	$13.1M	2025-12-31	2026-03-09	10-K	26-098491
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$297.0M	2025-12-31	2026-03-09	10-K	26-098491
8	operating income	us-gaap:OperatingIncomeLoss	-$79.5M	2025-12-31	2026-03-09	10-K	26-098491
9	book equity	us-gaap:StockholdersEquity	$212.5M	2025-12-31	2026-03-09	10-K	26-098491
10	liabilities	us-gaap:Liabilities	$13.7M	2025-12-31	2026-03-09	10-K	26-098491
11	revenue	us-gaap:Revenues	$0	2025-12-31	2026-03-09	10-K	26-098491
12	revenue	us-gaap:Revenues	$0	2024-12-31	2025-03-10	10-K	25-035910
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$193,000	2025-12-31	2026-03-09	10-K	26-098491
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$43.1M	2024-12-31	2026-03-09	10-K	26-098491
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$340,000	2024-12-31	2026-03-09	10-K	26-098491
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$58.6M	2023-12-31	2025-03-10	10-K	25-035910
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$256,000	2023-12-31	2025-03-10	10-K	25-035910
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$51.3M	2022-12-31	2024-03-19	10-K	24-033492
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$918,000	2022-12-31	2024-03-19	10-K	24-033492
20	assets	us-gaap:Assets	$289.6M	2023-12-31	2025-03-10	10-K	25-035910
21	assets	us-gaap:Assets	$341.1M	2022-12-31	2024-03-19	10-K	24-033492
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	61,672,279	2026-03-02	2026-03-09	10-K	26-098491
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	56,762,678	2025-03-06	2025-03-10	10-K	25-035910

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.